2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 393-396
This session explores how artificial intelligence, advanced molecular technologies, and innovative model systems are transforming hematologic diagnostics and precision medicine. Presentations span AI-enabled digital pathology and CBC-based immune profiling, rapid genomic testing in AML, computational prediction of cancer immunogenicity, and emerging platforms for therapeutic response testing—highlighting the evolution from traditional morphology and molecular assays toward integrated, data-driven diagnostics.
Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Emerging Technologies, Treatment Considerations, Drug Development, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, CLL, Research, Fundamental Science, Translational Research, Study Population, Human
PAPER

143 Pan-allelic prediction of peptide-HLA stability resolves CD8+ T cell immunogenicity for cancer antigen prioritization

Luis O Correa-Medero, PhD, Marta Wilbrink2, Jessika Baral3, Emma Duggan4, Kasidet Manakongtreecheep, PhD5, Natalie Clark, PhD6, Steven A Carr, PhD7, Derin B. Keskin8, Catherine J. Wu, MD9, Jenn G Abelin, PhD10, Nir Hacohen, PhD11
1 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
2 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
3 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
4 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
5 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
6 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
7 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
11 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States

New genomic and analytic platforms are increasingly revealing novel classes of antigens that promise to expand the immunologically targetable landscape of hematologic malignancies, which have been conventionally characterized as lower mutation burden and hence have only a limited repertoire of canonical neoantigens. Such antigens include those arising from the 'dark proteome', including those derived from noncanonical open reading frames (ncORFs) and endogenous retroviruses (ERVs), and these offer a compelling alternative pool of broadly shared, cancer-specific targets. 

The potentially vast number of candidate ncORF antigens creates a prioritization bottleneck. Current affinity-based predictors fail to implicitly encode peptide-human leukocyte antigen (pHLA) stability, a superior and well-acknowledged determinant of CD8? T cell immunogenicity. We hypothesized that a scalable, user-defined stability assay combined with a pan-allelic predictive model could systematically define the structural determinants of stability, robustly predict in vivo immunogenicity, and effectively prioritize dark proteome targets for antigen-targeting therapies for blood malignancies. We thus developed HLAglyph, a highly scalable platform for generating user-defined pHLA stability data. HLAglyph couples oligonucleotide-encoded peptide libraries expressed in E. coli (Pepyrus) with single-chain HLA-beta-2-microglobulin constructs and chaperone enzymes to enable cytoplasmic refolding (HLAplex). Following purification, pHLA complexes were subjected to thermal proteome profiling (TPP) across a 30°C to 75°C temperature gradient and quantified using TMT-enabled Mass Spectrometry to derive high-confidence melting temperatures (Tm). To enable in silico modeling, we developed HLAres, an ESM-2–based pan-allelic stability predictor finetuned from a binding-prediction backbone via regression against HLAglyph Tm data. Immunogenicity was evaluated both computationally via curated CEDAR datasets and functionally in vivo via IFN-γ ELISpot in HLA-A*11:01 transgenic mice. 

Profiling of sequence-divergent allotypes (A*11:01, A*02:01, B*07:02) revealed that HLAglyph generates robust, highly reproducible Tm data (standard deviation < 3°C across replicates), recovering a substantially broader sequence space than endogenous cell-line TPP. Binding affinity correlated only weakly with measured Tm, demonstrating that stability constitutes non-redundant biophysical information. Our predictive model, HLAres, accurately learned these determinants, achieving Spearman correlations > 0.8 and root-mean-square errors (RMSE) < 2°C on held-out peptides, while successfully generalizing to unseen alleles.

Crucially, both measured and predicted stability successfully stratified CD8? T cell immunogenicity. In transgenic mouse models immunized with an affinity-matched panel of neoantigen-like peptides, T cell responses strictly tracked with pHLA stability. Furthermore, among intermediate-affinity binders (%rank 0.5–2), a range where affinity-based ranking fails to differentiate targets, stability effectively separates immunogenic and non-immunogenic peptides. 

Our experimental and machine learning based approaches overcome the limitations of current antigen prioritization pipelines by enabling the scalable measurement and accurate prediction of pHLA stability. By resolving immunogenicity in sequence spaces where binding affinity is uninformative, this framework provides a highly discriminating tool to prioritize vast pools of shared ncORF and ERV targets, accelerating the development of potent, off-the-shelf cancer antigen targeting therapies, such as personalized vaccines for hematologic malignancies.

Luis O Correa-Medero, PhD: No relevant conflicts of interest to declare.